Metformin has been shown to increase the sensitivity cancer cells to oxidative stress and therapeutic drugs [34–37], through AMP-activated protein kinase (AMPK) and the mechanistic target of rapamycin (mTOR) pathway [38, 39]. The gene discussed is MTOR; the disease is cancer.